Evidence map›Paper›PMID 39806873›Full record

ArticleOrganic letters2025

Photoredox-Catalyzed Site-Selective Intermolecular C(sp

Reiji Abe, Kazunori Nagao, Tomohiro Seki, Dai Hata, Yusuke Sasaki, Hirohisa Ohmiya

Abstract read
In one paragraph

Article in Organic letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Reiji AbeInstitute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan.
Kazunori NagaoInstitute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan.ORCID 0000-0003-3141-5279
Tomohiro SekiResearch, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Dai HataResearch, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Yusuke SasakiResearch, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Hirohisa OhmiyaInstitute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan.ORCID 0000-0002-1374-1137

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

4'-Selective alkylation of nucleosides has been recognized as one of the ideal and straightforward approaches to chemically modified nucleosides, but such a transformation has been scarce and less explored. In this Letter, we combine a visible-light-mediated photoredox catalysis and hydrogen atom transfer (HAT) auxiliary to achieve β-C(sp

Identifiers

PMID39806873
PMCPMC11773563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.